Comparative Pharmacology
Head-to-head clinical analysis: AMJEVITA versus ERELZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMJEVITA versus ERELZI.
AMJEVITA vs ERELZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses that are induced or regulated by TNF-α, including expression of adhesion molecules, chemotaxis, and pro-inflammatory cytokine release.
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human IgG1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Subcutaneous injection: 40 mg every other week; for patients with Crohn disease, an initial dose of 160 mg (given as four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) followed by 80 mg at week 2 and 40 mg every other week starting at week 4.
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10-20 days) in patients receiving 40 mg every other week. This long half-life supports biweekly dosing.
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Adalimumab (AMJEVITA) is eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No intact drug is excreted in urine. The Fe receptor-mediated recycling contributes to long half-life.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor